16 febbraio 2024 – Walder Wyss advised CRISPR Therapeutics AG (NASDAQ: CRSP), a Switzerland-based biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, on the USD 280 million investment of a select group of institutional investors in CRISPR in a registered direct offering. The financing was led by EcoR1 Capital and SR One with participation from existing investors and a leading healthcare specialist investor. The financing is expected to close on or about February 27, 2024, subject to customary closing conditions.

The Walder Wyss team was led by Alex Nikitine (Partner) and Iliana Djagova (Counsel) and further included André Kuhn (Partner), Christian A. Schmid (Associate), Viktoriya Chernaya (Associate) and Fabian Akeret (Associate) (all Corporate/M&A/Capital Markets) and Maurus Winzap (Partner, Tax).